Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will present additional data from the pivotal Phase 3 ...

CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...

Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal ...

CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...

The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...

BMO Capital lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $45 from $60 and keeps a Market Perform rating on the shares.

Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three posters at the ...

While investing in biotech stocks can be risky due to clinical trial failures and regulatory hurdles, successful drug approvals can result in massive stock gains. Let’s look at two such growth stocks ...

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its ...

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...